Ian A. York

TL;DR: Cell-based Ag-presentation analysis was consistent with changes in the substrate inhibition constant Ki, supporting that ERAP1 allelic composition may affect Ag processing in vivo and proposing that these phenomena should be taken into account when evaluating the possible link between Ag processing and autoimmunity.

TL;DR: 21WxSLVK26 is a novel functional domain that regulates Vif activity toward both A3F and A3G and is a potential drug target to inhibit VifActivity and block HIV-1 replication.

TL;DR: Findings suggest that one mechanism underlying AS pathogenesis may involve an altered ability for AS patients harboring both HLA-B27 and high AS risk ERAP1 alleles to correctly display a variety of peptides to the adaptive arm of the immune system, potentially exposing such individuals to higher AS risk due to abnormal display of pathogen or self-derived peptides by the adaptive immune system.

TL;DR: Two novel functional domains, 81LGxGxxIxW89 and 171EDRW174, identified via sequence analysis of more than 2,000 different HIV-1 Vif proteins, could become new targets for inhibition of Vif activity during HIV replication.

TL;DR: It is shown that BH-deficient cells from mice are unimpaired in their ability to present epitopes from N-extended precursors or whole Ags and express normal levels of MHC class I molecules, and BH does influence presentation of some Ags, although its role is largely redundant with other aminopeptidases.